Non-Hodgkin lymphoma
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Non-Hodgkin lymphoma
- Therapeutic area
- Hematology
- non-Hodgkin lymphoma
- NHL
- non-Hodgkin lymphoma
- non-Hodgkin's lymphoma
- non-Hodgkin's lymphoma (NHL)
- non-Hodgkins lymphoma
- Severity
- Severe
- Hematology
- Oncology
- MONDO ID
- MONDO:0018908
- Parent condition
- MONDO:0005062
Related records
Broader conditions (13)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (159)
- A53 diffuse large B-cell lymphoma
- Acute biphenotypic leukemia
- Acute lymphoblastic leukemia
- Adult acute lymphoblastic leukemia
- Adult T-cell leukemia/lymphoma
- Aggressive B-cell non-Hodgkin lymphoma
- Aggressive NK-cell leukemia
- ALK-negative anaplastic large cell lymphoma
- ALK-positive anaplastic large cell lymphoma
- ALK-positive large B-cell lymphoma
- Anaplastic large cell lymphoma
- Angioimmunoblastic T-cell lymphoma
- B acute lymphoblastic leukemia with DUX4 rearrangement
- B acute lymphoblastic leukemia with PAX5 P80R mutation
- B-cell acute lymphoblastic leukemia
- B-cell acute lymphoblastic leukemia with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)
- B-cell adult acute lymphocytic leukemia
- B-cell childhood acute lymphoblastic leukemia
- B-cell chronic lymphocytic leukemia
- B-cell non-Hodgkin lymphoma
Trials (1,135)
- 'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL
- (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).
- 124I-FIAU Imaging in EBV and KSHV Associated Cancers
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
- 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
- 9-ING-41 in Patients With Advanced Cancers
- A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.
- A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
- A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
- A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
- A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae
- A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
- A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers
- A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Approved drugs (11)
- Bendamustine hydrochloride
- Brentuximab vedotin
- Carmustine
- Doxorubicin hydrochloride
- Idelalisib
- Melphalan hydrochloride
- Methotrexate
- Methotrexate sodium
- Pixantrone dimaleate
- Plerixafor
- Rituximab
Drugs in development (293)
- 1018 ISS Phase 2
- AB-101 Phase 1
- Abemaciclib Phase 1
- Abexinostat Phase 1
- ABT-510 Phase 2
- Acalabrutinib Phase 2
- Acetaminophen Phase 2
- ADG-106 Phase 1
- Aflibercept Phase 1
- AFM-11 Phase 1
- AG-24322 Phase 1
- Agatolimod sodium Phase 2
- Aldesleukin Phase 2
- Alemtuzumab Phase 1
- Allopurinol Phase 3
- Amifostine Phase 2
- Amoxicillin Phase 3
- ANTI-TAC 90 Y-HAT Phase 1
- Antineoplaston A10 Phase 2
- Apilimod mesylate Phase 2
Other linked drugs (10)
- Azercabtagene zapreleucel
- Cerdulatinib
- Febarbamate
- Iodine
- Nadravaleucel
- Nimesulide
- Orvacabtagene autoleucel
- Pirtobrutinib
- Trofosfamide
- Yttrium Y 90 epratuzumab